$4 generic antidepressant significantly reduces COVID-19 hospitalizations, clinical trial finds

By The Blaze —— Bio and Archives--October 29, 2021

News Headlines | Comments | Back To Full Article

An inexpensive, generic antidepressant has been shown to significantly reduce the risk of severe COVID-19 in clinical trials. Fluvoxamine — a readily available pill used to treat depression and obsessive-compulsive disorder — dramatically reduces serious illness and death from COVID-19 when prescribed early, according to a study published in the journal Lancet Global Health.-- More...

Read Full Article...

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy

CFP Comments

Comments

Support Canada Free Press

Recommended by Canada Free Press